William Blair upgraded Genmab (GMAB) to Outperform from Market Perform.Optimize Your Investment Research with SparkEffectively assess a stock's ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

Genmab (GMAB – Research Report) received a Buy rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

Genmab A/S (Nasdaq: GMAB) said on Monday that Johnson & Johnson (J&J) has decided not to exercise its option to obtain a ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in ...

Genmab (GMAB) reported strong Q4 2024 results last week and provided 2025 revenue guidance that was slightly ahead of the Street consensus and expense guidance that was below expectations.

Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...

Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation ...